NRAS mutations in melanoma promote RAS-MEK signaling cascade by switching their signaling from BRAF to CRAF, facilitated by the disruption of the cAMP-PKA inhibitory pathway on CRAF activity [94]. Here, NRAS is linked to melanoma.